2H-Imidazo[4,5-b]pyridin-2-one, 1-(1,1-dimethylethyl)-1,3-dihydro- | 1380487-27-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2H-Imidazo[4,5-b]pyridin-2-one, 1-(1,1-dimethylethyl)-1,3-dihydro-
• 英文别名: 1-tert-butyl-3H-imidazo[4,5-b]pyridin-2-one
• CAS: 1380487-27-3
• 化学式: C₁₀H₁₃N₃O
• 分子量: 191.23
• InChiKey: DPYNNJSISFEUJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Cgrp Receptor Antagonists
  申请人：Paone Daniel V.

  公开号：US20080261972A1

  公开（公告）日：2008-10-23

  Compounds of Formula (I), (where variables R 1 , A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  式(I)的化合物（其中变量R1、A、B、W、X、Y和Z如本文所定义），可用作CGRP受体的拮抗剂，并可用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗CGRP参与的这些疾病的方法。
• P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
  申请人：Burgey Christopher S

  公开号：US20100266714A1

  公开（公告）日：2010-10-21

  The subject invention relates to novel P2X 3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X 3 receptor subunit modulator.

  本发明涉及一种新型的P2X3受体拮抗剂，它在治疗与疼痛有关的疾病状态中发挥关键作用，特别是可以使用P2X3受体亚单位调节剂治疗的外周疼痛、炎性疼痛或组织损伤疼痛。
• Quinazolinone Compounds and Derivatives Thereof
  申请人：AMGEN INC.

  公开号：US20150225396A1

  公开（公告）日：2015-08-13

  Compounds of Formula I are useful inhibitors of tankyrase. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

  公式I的化合物是坦克酰酶的有用抑制剂。公式I的化合物具有以下结构：其中变量的定义在此提供。
• CGRP Receptor Antagonists
  申请人：Heptares Therapeutics Limited

  公开号：US20170121331A1

  公开（公告）日：2017-05-04

  The disclosures herein relate to novel compounds of formula wherein R 1 , R 2 and R 3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
• COMPOUNDS
  申请人：The University of Sheffield

  公开号：US20210113534A1

  公开（公告）日：2021-04-22

  Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , X, X 1 , X 2 , X 3 , L 1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM 2 ). Also disclosed are the compounds for use in the treatment of diseases modulated AM 2 , including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.